Toxicité pulmonaire induite par l’osimertinib - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Revue des Maladies Respiratoires Année : 2022

Pulmonary manifestations induced by osimertinib

Toxicité pulmonaire induite par l’osimertinib

Résumé

Introduction - The third-generation tyrosine kinase inhibitor (TKI) osimertinib is recommended as a first-line treatment in advanced non-small cell lung cancer harboring an activating mutation of Epidermal Growth Factor Receptor (EGFR). Adverse pulmonary events related to osimertinib exposure have been reported, primarily in Japanese patients. They rarely occur in the Caucasian population. Observation - Herein we report two clinical cases of osimertinib-induced lung toxicities in patients diagnosed with advanced lung adenocarcinoma harboring an EGFR mutation. In the first case, interstitial pneumonia was asymptomatic and evolved favorably after osimertinib discontinuation. The second patient presented a more extensive form of lung injuries and despite systemic corticosteroid therapy, the evolution was fatal. Conclusion - Osimertinib-related lung toxicities remain exceptional. While most forms are mild, consideration of TKI treatment discontinuation may be necessitated. Introduction of another TKI or rechallenge with osimertinib might be considered along with corticosteroid therapy if necessary. Diffuse alveolar damage is a pejorative prognostic factor.
Fichier principal
Vignette du fichier
LE GUEN et al -2021-Toxicité pulmonaire induite par l’osimertinib.pdf (6.06 Mo) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03514711 , version 1 (08-04-2022)

Licence

Paternité - Pas d'utilisation commerciale

Identifiants

Citer

Y Le Guen, M Lederlin, L Triquet, M Lesouhaitier, Y Le Tulzo, et al.. Toxicité pulmonaire induite par l’osimertinib. Revue des Maladies Respiratoires, 2022, 39 (1), pp.62-66. ⟨10.1016/j.rmr.2021.12.002⟩. ⟨hal-03514711⟩
139 Consultations
146 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More